Brokerages Set Nektar Therapeutics (NASDAQ:NKTR) Price Target at $49.33

Nektar Therapeutics (NASDAQ:NKTR) has received an average recommendation of “Hold” from the eighteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $49.33.

NKTR has been the subject of a number of recent research reports. Zacks Investment Research downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating and set a $34.00 price objective for the company. in a research note on Wednesday, July 31st. BidaskClub downgraded shares of Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 16th. William Blair reissued a “buy” rating on shares of Nektar Therapeutics in a research note on Friday, August 9th. Jefferies Financial Group downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $59.00 to $23.00 in a research note on Friday, August 9th. Finally, HC Wainwright reissued a “hold” rating on shares of Nektar Therapeutics in a research note on Tuesday, August 13th.

NASDAQ:NKTR traded down $1.02 during trading hours on Thursday, reaching $18.91. The company’s stock had a trading volume of 2,184,471 shares, compared to its average volume of 2,061,900. The company has a market capitalization of $3.42 billion, a P/E ratio of 5.00 and a beta of 2.71. Nektar Therapeutics has a 12 month low of $16.56 and a 12 month high of $62.40. The company has a debt-to-equity ratio of 0.22, a quick ratio of 13.97 and a current ratio of 14.09. The stock has a 50 day moving average price of $19.36 and a two-hundred day moving average price of $29.89.



Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.17. The company had revenue of $23.32 million during the quarter, compared to the consensus estimate of $26.65 million. Nektar Therapeutics had a negative net margin of 354.90% and a negative return on equity of 25.25%. Nektar Therapeutics’s revenue for the quarter was down 97.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.33 earnings per share. As a group, analysts predict that Nektar Therapeutics will post -2.85 EPS for the current fiscal year.

In related news, SVP Stephen K. Doberstein acquired 15,000 shares of the company’s stock in a transaction dated Thursday, September 5th. The shares were purchased at an average cost of $17.28 per share, with a total value of $259,200.00. Following the completion of the acquisition, the senior vice president now directly owns 107,668 shares of the company’s stock, valued at $1,860,503.04. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Lutz Lingnau sold 10,000 shares of the business’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $34.63, for a total transaction of $346,300.00. Following the sale, the director now directly owns 33,200 shares in the company, valued at $1,149,716. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 143,826 shares of company stock worth $3,706,037. Insiders own 4.02% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Macquarie Group Ltd. grew its holdings in shares of Nektar Therapeutics by 2.6% during the second quarter. Macquarie Group Ltd. now owns 170,400 shares of the biopharmaceutical company’s stock valued at $6,063,000 after buying an additional 4,300 shares during the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its holdings in shares of Nektar Therapeutics by 27.1% during the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 55,448 shares of the biopharmaceutical company’s stock valued at $1,973,000 after buying an additional 11,808 shares during the last quarter. Toronto Dominion Bank grew its holdings in shares of Nektar Therapeutics by 2.0% during the second quarter. Toronto Dominion Bank now owns 123,269 shares of the biopharmaceutical company’s stock valued at $4,385,000 after buying an additional 2,466 shares during the last quarter. Atria Investments LLC purchased a new stake in shares of Nektar Therapeutics during the second quarter valued at $240,000. Finally, Treasurer of the State of North Carolina grew its holdings in shares of Nektar Therapeutics by 16.6% during the second quarter. Treasurer of the State of North Carolina now owns 133,794 shares of the biopharmaceutical company’s stock valued at $4,760,000 after buying an additional 19,090 shares during the last quarter. 93.27% of the stock is currently owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Featured Story: How a Strangle Strategy is different from a Straddle Strategy

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.